DOI: https://dx.doi.org/10.18203/2320-6012.ijrms20221806
Published: 2022-06-28

Sneddon syndrome a case report and literature review

Rafael R. P. Leon, Iliana N. C. Sánchez, Jorge A. P. Reyes, Luis F. D. Valdez, Luis F. A. Romero, Carlos U. C. Corona, Diana K. S. Lopez, Marcos O. M. Chavez, Ivan A. S. Melgarejo, Marlene I. M. Vivanco

Abstract


Sneddon’s syndrome (SS) is characterized by livedo racemosa (LR) or reticularis and recurrent ischemic strokes. At the skin and brain level a non-inflammatory thrombotic vasculopathy is observed. Almost 80% of cases are women around 40 years old. The most accepted etiological proposal is an autoimmune and inflammatory mechanism versus the presence of thrombophilia. Neurological manifestations occur in 3 phases: prodromal symptoms (headache, dizziness, and vertigo), recurrent strokes, and early-onset dementia. Livedo racemosa has been reported to precede strokes by more than 10 years. Treatment is mainly based on secondary prophylaxis preventing a stroke with antiplatelet and antithrombotic agents. The neuropsychiatric prognosis is relatively poor with deficits in concentration, attention, visual perception, and visuospatial skills.


Keywords


Sneddon syndrome, Livedo racemosa, Ischemic strokes, Early dementia, Antiphospholipid antibodies, Thrombophilia

Full Text:

PDF

References


Sneddon I. Cerebro-vascular lesions and livedo reticularis. Ann Meet Br Assoc Dermatol. 1964;180-5.

Elmahi H, Mernissi F. Images in medicine Sneddon syndrome. Pan Af Med J. 2019;34-9.

Samanta D, Cobb S, Arya K. Sneddon Syndrome: A Comprehensive Overview. J Stroke Cerebrovasc Dis. 2019;28:2098-108.

Wu S, Xu Z, Liang H. Sneddon’s syndrome: a comprehensive review of the literature. Orphanet J Rare Dis. 2014;215:1-7.

Timoney I, Flynn A, Leonard N, Wynne B. Livedo racemosa: a cutaneous manifestation of Sneddon´s syndrome. BMJ. 2019;12:1-3.

Zelger B, Sepp N, Stockhammer G, Dosch E, Hilty E, Ofner D, et al. Sneddon’s syndrome. a long-term follow-up of 21 patients. Arch Dermatol. 1993;129:437-47.

Berciano J, Villagra N. Sneddon syndrome and non-bacterial thrombotic endocarditis: a clinicopathological study. J Neurol. 2018;1:1-3.

Rutter-Locher Z, Chen Z, Flores F, Basu T, Creamer D, Weeks R. Sneddon’s syndrome: it is all in the ectoderm. Pract Neurol. 2016;16:300-3.

Vallés L, González M, Polo I, Rivera R, Vanaclocha F. Sneddon´s syndrome. Med Cutan Iber Lat Am. 2010;38(1):37-40.

Bolayir E, Yilmaz A, Kugu N, Erdogan H, Akyol M, Akyuz A. Sneddon ́s Syndrome: clinical and laboratory análisis of 10 cases. Acta Med. 2004;58(2):59-65.

Aboud D, Broshtilova V, Aboud K, Hawsawi A. Dermatological aspects of cere- brovascular diseases. Acta Dermatoven APA. 2005;14(1):9-14.

Forchhammer S, Metzler G, Ghoreschi. Long-term follow-up of early-onset Sneddon syndrome: A case report. JAAD Case Rep. 2018;4(9):880-3.

Frances C, Papo T, Wechsler B, Laporte JL, Biousse V, Piette JC. Sneddon syndrome with or without antiphospholipid anti- bodies. A comparative study in 46 patients. Medicine (Balti- more). 1999;78(4):209-19.

Wohlrab J, Fischer M, Wolter M, Marsch W. Diagnostic impact and sensitivity of skin biopsies in Sneddon’s syndrome. A report of 15 cases. Br J Dermatol. 2001;145:285-8.

Hannon P, Kuo SH, Strutt A, York M, Kass J. Improvement of neurological symptoms and memory and emotional status in a case of seronegative Sneddon syndrome with cyclophosphamide. Clin Neurol Neurosurg. 2010;112:544-7.